PerkinElmer
check quantity

AlphaLISA BRD4_BD1 / H4 K5,8,12,16Ac Binding Kit, 500 points

This kit is designed for the detection of binding activity between bromodomain-containing protein 4, Bromodomain1: BRD4 (BD1) and acetylated histone H4 peptide (H4 K5,8,12,16Ac) using a homogeneous AlphaLISA assay (no wash steps). The assay allows screening of BRD4 inhibitors with a highly-specific substrate.

You successfully added item(s) to your cart

For research use only. Not for use in diagnostic procedures.

Part Number
Unit Size
List Price
Your Price
Quantity
AL609C
500 assay points
721.00 EUR
more
Buy Now

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Detail Information

This kit is designed for the detection of binding activity between bromodomain-containing protein 4, Bromodomain1: BRD4 (BD1) and acetylated histone H4 peptide (H4 K5,8,12,16Ac) using a homogeneous AlphaLISA assay (no wash steps). The assay allows screening of BRD4 inhibitors with a highly-specific substrate.

Together with Epicypher, a worldwide reputed biotech specialized in the production of proteins and peptides for reader assays, we have developed AlphaLISA® kits to measure the binding of BRD4 and P300 reader domains to various histone H2, H3 or H4 peptide tails. AlphaLISA detection of epigenetic marks uses glutathione (GSH) AlphaLISA Acceptor beads to capture the GST-tagged bromodomains and Streptavidin-coated Donor beads to capture the biotinylated peptide. Donor beads and Acceptor beads come into proximity through BRD4 binding to the acetylated histone H4 peptide. Excitation of the Donor beads provokes the release of singlet oxygen that triggers a cascade of energy transfer reactions in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Bromodomains (BRDs) are a class of epigenetic reader molecules that translate the acetylation state of histones into downstream cell-signaling events. Due to their importance in these physiological processes, bromodomains are believed to be involved in many disease states, including cancer and atherosclerosis. BRD4, currently the most studied member of the BET (bromodomain and extra terminal domain) family, contains two tandem bromodomains (BD1 and BD2) and an extraterminal (ET) domain. BRD4 directly maintains the acetylation state of histones and preferentially binds to acetylated H3 and H4. The recent discovery of potent and highly specific bromodomain family inhibitors, such as JQ1, has stimulated intensive research activity, therefore BRD4 has been considered as an important therapeutic target. This assay can be used to determine the binding activity of BRD4 with acetylated histone H4 peptide and to measure the inhibition of this binding.

Specifications

Assay Target Histone H4
Assay Target Class Histone
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Molecular Modification Acetylation
Product Brand Name AlphaLISA
Shipping Condition Dry Ice
Therapeutic Area Epigenetics
Unit Size 500 assay points